Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer

Hosoda, Mitsuchika; Yamamoto, Mitsugu; Nakano, Kiichiroh et al.

Breast Cancer Research and Treatment, 2014, 144(2), 249-261

Permalink : https://hdl.handle.net/2115/58539

このアイテムのアクセス数:1,348件（2026-08-15 03:00 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
Breast Cancer Res Treat_144(2)_249-261 pdf 3.39 MB 1,782

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/58539
タイトル
Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer
著者
Hosoda, Mitsuchika ; Yamamoto, Mitsugu ; Nakano, Kiichiroh ; Hatanaka, Kanako C. ; Takakuwa, Emi ; Hatanaka, Yutaka ; Matsuno, Yoshihiro ; Yamashita, Hiroko
e-Rad_Researcher
40443931
著者名
Hosoda, Mitsuchika
著者名
Yamamoto, Mitsugu
著者名
Nakano, Kiichiroh
著者名
Hatanaka, Kanako C.
著者名
Takakuwa, Emi
e-Rad_Researcher
30589924
著者名
Hatanaka, Yutaka
著者名
Matsuno, Yoshihiro
e-Rad_Researcher
70332947
著者名
Yamashita, Hiroko
言語
英語
キーワード
Breast cancer
Progesterone receptor
FOXA1
GATA3
Ki67
p53
発行日
2014-04
出版者
Springer
収録物名
Breast Cancer Research and Treatment
巻(号)
144(2)
ページ
249-261
抄録
Estrogen receptor (ER) is essential for estrogendependent growth, and its level of expression is considered a crucial determinant of response to endocrine therapy and prognosis in ER-positive breast cancer. On the other hand, the clinical role of progesterone receptor (PgR) in ER-positive breast cancer remains controversial, although testing of PgR by immunohistochemistry (IHC) has become routine. Recent studies indicated that plasma estradiol levelswere related to the expression levels of estrogen-responsive genes in ER-positive breast cancer tissues in both pre- and postmenopausal women. In this study, we analyzed the expression levels of strogenresponsive genes (PgR and TFF1), a progesterone-responsive gene (RANKL), ER-related genes (FOXA1 and GATA3), HER2, Ki67 and p53 in ER-positive, HER2-negative breast cancer tissues by IHC. Correlations between the expression levels of these molecular markers and clinicopathological factors, including prognosis, were compared between pre- and postmenopausal women. Serum levels of estrone, estradiol, progesterone, and testosterone were also measured. Expression levels of PgR, TFF1, RANKL, and GATA3 were significantly higher in premenopausal women than in postmenopausal women. Serum estradiol levels were positively correlated with Ki67 labeling index (LI) in premenopausal women, but not in postmenopausal women. High expression of FOXA1 and GATA3 was significantly associated with improved diseasefree survival in premenopausal women, but not in postmenopausal women, whereas high expression of PgR and low expression of p53 were significantly correlated with the improved disease-free survival in postmenopausalwomen, but not in premenopausalwomen.Moreover, the best cutoff points of Ki67 LI for disease-free survival were 30 % for premenopausal women and 14 % for postmenopausal women. Expression levels of ER, TFF1, and RANKL were not associated with the disease-free survival in either pre- or postmenopausal women. Our results suggest that the mechanisms of development and estrogen-dependent growth ofER-positive breast cancer might differ according to menopausal status.
資源タイプ
学術雑誌論文
出版タイプ
Accepted Manuscript
権利情報
The final publication is available at link.springer.com
PISSN
0167-6806
EISSN
1573-7217
NCID
AA10623184
関連情報
PMID
24549642
関連情報 (isVersionOf)
出版社版DOI
https://doi.org/10.1007/s10549-014-2867-0